Real-world outcomes among US Merkel cell carcinoma patients initiating immune checkpoint inhibitors or chemotherapy

Retrospectively assessed treatment patterns and clinical and economic outcomes in Merkel cell carcinoma (MCC) patients receiving recommended first-line regimens. MCC patients newly treated with either immune checkpoint inhibitors (ICIs) or chemotherapies (CTs) were selected from the Veterans Health...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Future oncology (London, England) England), 2020-11, Vol.16 (31), p.2521-2536
Hauptverfasser:	Chandra, Sunandana, Zheng, Ying, Pandya, Shivani, Yu, Ting, Kearney, Mairead, Wang, Li, Kim, Ruth, Phatak, Hemant
Format:	Artikel
Sprache:	eng
Schlagworte:	Blood diseases Cancer therapies Chemotherapy Clinical trials Comorbidity Decision support systems Disease duration of treatment health care resource utilization immune checkpoint inhibitors Immune system Life Sciences & Biomedicine Merkel cell carcinoma Metastasis Mortality Oncology Patients Pharmacy Radiation therapy recommended chemotherapy Science & Technology Skin cancer Surgery survival time to next treatment Transplants & implants Tumors Veterans Health Administration
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!